Literature DB >> 24085395

Virus-like particles produced in Saccharomyces cerevisiae elicit protective immunity against Coxsackievirus A16 in mice.

Hui Zhao1, Hao-Yang Li, Jian-Feng Han, Yong-Qiang Deng, Yue-Xiang Li, Shun-Ya Zhu, Ya-Ling He, E-De Qin, Rong Chen, Cheng-Feng Qin.   

Abstract

Hand, foot, and mouth disease (HFMD) has caused significant morbidity and mortality in the Asia-Pacific regions, particularly in infants and young children. Coxsackievirus A16 (CA16) represents one of the major causative agents for HFMD, and the development of a safe and effective vaccine preventing CA16 infections has become a public health priority. In this study, we have developed a yeast system for the production of virus-like particles (VLPs) for CA16 by co-expressing P1 and 3CD of CA16 in Saccharomyces cerevisiae. These VLPs exhibit similarity in both protein composition and morphology as empty particles from CA16-infected cells. Immunization with CA16 VLPs in mice potently induced CA16-specific IgG and neutralization antibodies in a dose-dependent manner. IgG subclass isotyping revealed that IgG1 and lgG2b were dominantly induced by VLPs. Meanwhile, cytokine profiling demonstrated that immunization with VLPs significantly induced the secretion of IFN-γ, indicating potent cellular immune response. Furthermore, in vivo challenge experiments showed that passive immunization with anti-VLPs sera conferred full protection against lethal CA16 challenge in neonate mice. Taken together, our data demonstrated that VLPs produced in yeast might have the potential to be further developed as a vaccine candidate against HFMD.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24085395     DOI: 10.1007/s00253-013-5257-3

Source DB:  PubMed          Journal:  Appl Microbiol Biotechnol        ISSN: 0175-7598            Impact factor:   4.813


  12 in total

Review 1.  Is a multivalent hand, foot, and mouth disease vaccine feasible?

Authors:  Michel Klein; Pele Chong
Journal:  Hum Vaccin Immunother       Date:  2015-05-26       Impact factor: 3.452

2.  Structure, Immunogenicity, and Protective Mechanism of an Engineered Enterovirus 71-Like Particle Vaccine Mimicking 80S Empty Capsid.

Authors:  Xiaoli Wang; Zhiqiang Ku; Xiang Zhang; Xiaohua Ye; Jinhuan Chen; Qingwei Liu; Wei Zhang; Chao Zhang; Zhenglin Fu; Xia Jin; Yao Cong; Zhong Huang
Journal:  J Virol       Date:  2017-12-14       Impact factor: 5.103

3.  Cryo-electron microscopy study of insect cell-expressed enterovirus 71 and coxsackievirus a16 virus-like particles provides a structural basis for vaccine development.

Authors:  Minqing Gong; Hongtao Zhu; Jun Zhou; Chunting Yang; Jing Feng; Xiaojun Huang; Gang Ji; Honglin Xu; Ping Zhu
Journal:  J Virol       Date:  2014-03-26       Impact factor: 5.103

4.  Comparative study of the immunogenicity in mice and monkeys of an inactivated CA16 vaccine made from a human diploid cell line.

Authors:  Erxia Yang; Chen Cheng; Ying Zhang; Jingjing Wang; Yanchun Che; Jing Pu; Chenghong Dong; Longding Liu; Zhanlong He; Shuaiyao Lu; Yuan Zhao; Li Jiang; Yun Liao; Congwen Shao; Qihan Li
Journal:  Hum Vaccin Immunother       Date:  2014-02-28       Impact factor: 3.452

5.  Evaluation of monovalent and bivalent vaccines against lethal Enterovirus 71 and Coxsackievirus A16 infection in newborn mice.

Authors:  Shiyang Sun; Liping Jiang; Zhenglun Liang; Qunying Mao; Weiheng Su; Huafei Zhang; Xiaojun Li; Jun Jin; Lin Xu; Dandan Zhao; Peihu Fan; Dong An; Ping Yang; Jingcai Lu; Xiuping Lv; Bo Sun; Fei Xu; Wei Kong; Chunlai Jiang
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

6.  Novel recombinant chimeric virus-like particle is immunogenic and protective against both enterovirus 71 and coxsackievirus A16 in mice.

Authors:  Hui Zhao; Hao-Yang Li; Jian-Feng Han; Yong-Qiang Deng; Shun-Ya Zhu; Xiao-Feng Li; Hui-Qin Yang; Yue-Xiang Li; Yu Zhang; E-De Qin; Rong Chen; Cheng-Feng Qin
Journal:  Sci Rep       Date:  2015-01-19       Impact factor: 4.379

Review 7.  EV-A71 vaccine licensure: a first step for multivalent enterovirus vaccine to control HFMD and other severe diseases.

Authors:  Qunying Mao; Yiping Wang; Lianlian Bian; Miao Xu; Zhenglun Liang
Journal:  Emerg Microbes Infect       Date:  2016-07-20       Impact factor: 7.163

8.  Coxsackievirus A16 utilizes cell surface heparan sulfate glycosaminoglycans as its attachment receptor.

Authors:  Xueyang Zhang; Jinping Shi; Xiaohua Ye; Zhiqiang Ku; Chao Zhang; Qingwei Liu; Zhong Huang
Journal:  Emerg Microbes Infect       Date:  2017-07-26       Impact factor: 7.163

9.  Recombinant tandem multi-linear neutralizing epitopes of human enterovirus 71 elicited protective immunity in mice.

Authors:  Yue-Xiang Li; Hui Zhao; Rui-Yuan Cao; Yong-Qiang Deng; Jian-Feng Han; Shun-Ya Zhu; Jie Ma; Long Liu; E-De Qin; Cheng-Feng Qin
Journal:  Virol J       Date:  2014-05-06       Impact factor: 4.099

10.  Virus-Like Particles Produced in Pichia Pastoris Induce Protective Immune Responses Against Coxsackievirus A16 in Mice.

Authors:  Qianjin Feng; Yaqing He; Jiahai Lu
Journal:  Med Sci Monit       Date:  2016-09-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.